clinical trial
NICE recommends NHS use of mirikizumab for Crohn’s disease
July 11, 2025Medical Communications, Research and Development Crohn’s disease, Gastrointestinal tract, Medicines and Healthcare products Regulatory Agency, NHS, National Institute for Health and Care Excellence (NICE), bowel disease, clinical trial
Eli Lilly (Lilly) has announced that the National Institute for Health and Care Excellence (NICE) has recommended mirikizumab (omvoh) for …
FDA grants accelerated approval for advanced non-small cell lung cancer treatment
July 4, 2025Medical Communications, Research and Development Breakthrough Therapy Designation, Oncology, US Food and Drug Administration, Zegfrovy, clinical trial, non-small cell lung cancer, priority review
The US Food and Drug Administration (FDA) has granted accelerated approval to Dizal Therapeutic’s Zegfrovy (sunvozertinib) for the treatment of …
Johnson & Johnson seeks EMA approval to accelerate prostate cancer treatment
July 4, 2025Medical Communications, Research and Development European Medicines Agency, Genito-Urinary system, Johnson & Johnson, Oncology, clinical trial, prostate cancer
Johnson & Johnson has submitted an application to the European Medicines Agency for an indication extension of Akeega (niraparib and …
Ferring strengthens evidence for flexible dosing of follitropin delta in IVF
July 3, 2025Research and Development Ferring Pharmaceuticals, IVF, Reproductive health, clinical trial, fertility treatment, in vitro fertilisation, ovarian hyperstimulation syndrome, pregnancy, reproductive health, reproductive medicine
Ferring Pharmaceuticals has reported that a conventional 15µg/day starting dose of follitropin delta (Rekovelle) provides comparable efficacy and safety to …
SphingoTec’s PenKid leads the way in early detection of delayed graft function after kidney transplant
July 1, 2025Medical Communications, Research and Development Nephrology, PenKid, SphingoTec, biomarker, clinical trial, delayed graft function, kidney replacement therapy, kidney transplant, serum creatinine
SphingoTec has announced new findings validating the clinical utility of its kidney biomarker proenkephalin A 119-159 (PenKid) in assessing graft …
STENTiT treats first patient with regenerative stent for limb preservation
June 27, 2025Research and Development Cardiology, Medical University of Graz, STENTiT, chronic limb-threatening ischemia, clinical trial, limb amputation, peripheral artery disease, regenerative stent, resorbable fibrillated scaffold
STENTiT has announced the successful first patient implantation of its resorbable fibrillated scaffold (RFS), a new regenerative stent, as part …
Roche candidate shows early promise for treating haemophilia A
June 25, 2025Research and Development Chugai, Haematology, Roche, clinical trial, haemophilia a, prophylactic therapy
Roche has announced encouraging early results from its phase 1/2 trial of NXT007, an investigational bispecific antibody for haemophilia A. …
Eyestem completes phase 1 trial of retinal cell therapy with promising vision gains
June 20, 2025Research and Development Eyestem Research, Opthalmology, cell therapy, clinical trial, dry age-related macular degeneration, geographic atrophy
Eyestem Research has announced the successful completion of its phase 1 trial evaluating Eyecyte-RPE, an investigational cell therapy for geographic …
Johnson & Johnson presents promising data on leukaemia treatment
June 16, 2025Medical Communications, Research and Development European Hematology Association, Janssen-Cilag, Johnson & Johnson, Oncology, chronic lymphocytic leukaemia, clinical trial
Janssen-Cilag, a Johnson & Johnson company, has announced results from a matching-adjusted indirect comparison presented at this year’s European Hematology …
Bristol Myers Squibb reports positive results for psoriatic arthritis treatment
June 13, 2025Medical Communications, Research and Development European Alliance of Associations for Rheumatology, Rheumatology, bristol myers squibb, clinical trial, psoriatic arthritis
Bristol Myers Squibb (BMS) has presented new data from its phase 3 POETYK PsA-1 trial, showing that Sotyktu (deucravacitinib) significantly …
Lubrizol announces an important milestone for its novelpatented excipient, Apisolex™ polymer
June 10, 2025Research and Development Apisolex polymer, Good Manufacturing Practices (GMP) guidelines, Lubrizol, Pharmacy, clinical trial
June 10, 2025 – Lubrizol announces that an Apisolex™ polymer excipient-enabled drugformulation is in Phase 1 clinical trials. Introduced to …
Vertex presents promising new data from cystic fibrosis trials
June 9, 2025Medical Communications, Research and Development European Cystic Fibrosis Conference, Rare Diseases, Vertex, clinical trial, cystic fibrosis
Vertex Pharmaceuticals has presented new data showing the clinical and quality-of-life benefits of its cystic fibrosis (CF) therapies, particularly Alyftrek …
Corcept reports survival benefit in ALS trial of dazucorilant despite missing primary endpoint
June 9, 2025Research and Development Corcept Therapeutics, European Network to Cure ALS (ENCALS), Neurology, amyotrophic lateral sclerosis, clinical trial
Corcept Therapeutics has announced results from its phase 2 DAZALS study investigating dazucorilant in patients with amyotrophic lateral sclerosis (ALS), …
Study into treatment for rare condition in premature infants launches globally
June 9, 2025Research and Development Chiesi Farmaceutici, Elgan Pharma, Gastrointestinal tract, Paediatrics, clinical trial, intestinal malabsorption, premature infant health
Elgan Pharma, specialising in neonatology, and Italy-based biopharma, Chiesi Farmaceutici, have announced the dosing of the first participating infants in …
Trial into rare genetic disease Werner syndrome reports promising results
June 6, 2025Research and Development Chiba University, Niagen Bioscience, Rare Diseases, Werner Syndrome, clinical trial, rare genetic disease
Researchers at Chiba University, Japan, alongside Niagen Bioscience, have reported successful results from the world’s first trial of nicotinamide riboside …
Latest content
New CCO Ogburn joins Cori Clinical
Claris reports visual acuity gains with experimental LSCD treatment
Amphista doses first patient in AML trial of protein degrader
Jennings becomes President of Beckman Coulter Diagnostics
